Development and Evaluation of a Decision Aid for BRCA Carriers with Breast Cancer

BRCA+ breast cancer patients face high risk for a second breast cancer and ovarian cancer. Helping these women decide among risk-reducing options requires effectively conveying complex, emotionally-laden, information. To support their decision-making needs, we developed a web-based decision aid (DA) as an adjunct to genetic counseling. Phase 1 used focus groups to determine decision-making needs. These findings and the Ottawa Decision Support Framework guided the DA development. Phase 2 involved nine focus groups of four stakeholder types (BRCA+ breast cancer patients, breast cancer advocates, and genetics and oncology professionals) to evaluate the DA’s decision-making utility, information content, visual display, and implementation. Overall, feedback was very favorable about the DA, especially a values and preferences ranking-exercise and an output page displaying personalized responses. Stakeholders were divided as to whether the DA should be offered at-home versus only in a clinical setting. This well-received DA will be further tested to determine accessibility and effectiveness.

[1]  B. Rosen,et al.  Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation , 2007, Clinical genetics.

[2]  Jennifer M. Fortin,et al.  Identifying patient preferences for communicating risk estimates: A descriptive pilot study , 2001, BMC Medical Informatics Decis. Mak..

[3]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[4]  A. O'Connor.  Validation of a Decisional Conflict Scale , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.

[5]  V. Braun,et al.  Using thematic analysis in psychology , 2006 .

[6]  D J Schaid,et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.

[7]  R. Thomson,et al.  Decision aids for people facing health treatment or screening decisions. , 2003, The Cochrane database of systematic reviews.

[8]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[9]  Julie O. Culver,et al.  Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates. , 2011, Patient education and counseling.

[10]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[11]  J. Weitzel,et al.  Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. , 2003, Archives of surgery.

[12]  T. Walsh,et al.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.

[13]  Sarah M. Greene,et al.  Complications following bilateral prophylactic mastectomy. , 2005, Journal of the National Cancer Institute. Monographs.

[14]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[15]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[16]  Richard A. Krueger,et al.  Focus groups : a practical guide for applied research / by Richard A. Krueger , 1989 .

[17]  Marcia M. Boehmke,et al.  Survivorship considerations in adults with hereditary breast and ovarian cancer syndrome: state of the science , 2009, Journal of cancer survivorship : research and practice.

[18]  E. Legius,et al.  Surveillance Behavior and Prophylactic Surgery After Predictive Testing for Hereditary Breast/Ovarian Cancer , 2005, Behavioral medicine.

[19]  J. Weitzel,et al.  Concerns of women presenting to a comprehensive cancer centre for genetic cancer risk assessment , 2002, Journal of medical genetics.

[20]  R. Eeles,et al.  Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort , 2004, British Journal of Cancer.

[21]  I D Graham,et al.  Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. , 1999, Journal of the National Cancer Institute. Monographs.

[22]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[23]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[24]  Ellen Warner,et al.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Bingshu E. Chen,et al.  Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Susan L Neuhausen,et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Daal,et al.  Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Peter Tugwell,et al.  Randomized Trial of a Portable, Self-administered Decision Aid for Postmenopausal Women Considering Long-term Preventive Hormone Therapy , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[29]  H. Valdimarsdottir,et al.  Longitudinal Changes in Patient Distress following Interactive Decision Aid Use among BRCA1/2 Carriers , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[30]  Jessica S. Ancker,et al.  The Practice of Informatics: Design Features of Graphs in Health Risk Communication: A Systematic Review , 2006, J. Am. Medical Informatics Assoc..

[31]  Hsiu-Fang Hsieh,et al.  Three Approaches to Qualitative Content Analysis , 2005, Qualitative health research.

[32]  Amiram Gafni,et al.  Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. , 2004, JAMA.

[33]  W. Daal,et al.  Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation , 2004, British Journal of Cancer.

[34]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[35]  Susan M. Domchek,et al.  Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers , 2009, Journal of the National Cancer Institute.

[36]  M. Watson,et al.  Understanding the experience of prophylactic bilateral mastectomy: a qualitative study of ten women , 2000, Psycho-oncology.

[37]  Amiram Gafni,et al.  Are cancer-related decision aids effective? A systematic review and meta-analysis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  I. Jacobs,et al.  Surveillance or surgery? A description of the factors that influence high risk premenopausal women's decisions about prophylactic oophorectomy , 2001, Journal of medical genetics.

[39]  C. Magnant,et al.  Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[41]  Aileen Clarke,et al.  Developing a quality criteria framework for patient decision aids: online international Delphi consensus process , 2006, BMJ : British Medical Journal.

[42]  M. Rogers,et al.  Decision aids and breast cancer: do they influence choice for surgery and knowledge of treatment options? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  H. Valdimarsdottir,et al.  Decision making and decision support for hereditary breast-ovarian cancer susceptibility. , 2005, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[44]  J. E. Nash,et al.  Psychological responses to BRCA1 mutation testing: preliminary findings. , 1997, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[45]  K. Heimdal,et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.

[46]  T. Rebbeck,et al.  Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  T. Sellers,et al.  Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  W. Otten,et al.  Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  L. Esserman,et al.  Genetic/familial high-risk assessment , 2010 .

[50]  O. Olopade,et al.  Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update , 2006, International journal of cancer.

[51]  R. Thomson,et al.  Decision aids for people facing health treatment or screening decisions. , 2011, The Cochrane database of systematic reviews.

[52]  Janet Mancini Billson,et al.  Focus Groups: A Practical Guide for Applied Research , 1989 .

[53]  J. Weitzel,et al.  Contralateral Risk-Reducing Mastectomy in Young Breast Cancer Patients with and without Genetic Cancer Risk Assessment , 2008, Annals of Surgical Oncology.

[54]  Kimberly A. Neuendorf,et al.  The Content Analysis Guidebook , 2001 .

[55]  F. Modugno.  Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. , 2003, Gynecologic oncology.

[56]  J. Kirk,et al.  A Randomized Controlled Trial of a Decision Aid for Women at Increased Risk of Ovarian Cancer , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[57]  B. Ferrell,et al.  Quality of Life in Breast Cancer Survivors as Identified by Focus Groups , 1997, Psycho-oncology.

[58]  Suzanne O'Neill,et al.  Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. , 2009, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[59]  S. Narod,et al.  Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer , 2004, Familial Cancer.